Home Newsfeeds Lyra Therapeutics Q2 EPS $(0.43) Up From $(0.85) YoY

Lyra Therapeutics Q2 EPS $(0.43) Up From $(0.85) YoY

Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(0.43) per share. This is a 49.41 percent increase over losses of $(0.85) per share from the same period last year.

byBenzinga Newsdesk

August 9, 2022

1 minute read

Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(0.43) per share. This is a 49.41 percent increase over losses of $(0.85) per share from the same period last year.

Shares Of Carvana Halted To The Upside: What’s Going On?

By AJ Fabino

December 9, 12:20 PM

Shares of Carvana Co (NYSE: CVNA) are experiencing upside volatility Friday, following a report suggesting lenders do not expect the company to file for bankruptcy soon.

CVNA

Piper Sandler Maintains Overweight on Devon Energy, Lowers Price Target to $89

By Benzinga Newsdesk

February 22, 9:45 AM

Piper Sandler analyst Mark Lear maintains Devon Energy (NYSE:DVN) with a Overweight and lowers the price target from $96 to $89.

DVN

Amazon’s Voice Assistant Alexa Under Fire For Inaccurate Election Info

By Anusuya Lahiri

October 9, 10:57 AM

Amazon.Com, Inc's (NASDAQ: AMZN) voice assistant Alexa has been caught in the

AMZN

Codexis Clinches Deal With Nestlé Health Science, Eyes Up To $45M Milestone In EPI Treatment Breakthrough

By Akanksha Bakshi

December 27, 11:28 AM

Codexis, Inc. (NASDAQ: CDXS) entered a purchase deal with Nestlé S.A.(OTC: NSRGY) Nestlé Health Science for CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI).

CDXS

Lyra Therapeutics Q2 EPS $(0.43) Up From $(0.85) YoY

Related Posts

Shares Of Carvana Halted To The Upside: What’s Going On?

Piper Sandler Maintains Overweight on Devon Energy, Lowers Price Target to $89

Amazon’s Voice Assistant Alexa Under Fire For Inaccurate Election Info

Codexis Clinches Deal With Nestlé Health Science, Eyes Up To $45M Milestone In EPI Treatment Breakthrough